D1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 2, 1997, Pages 477-483

  Steele, Thomas D ^a   Hodges Jr , Donald B ^a   Levesque, Tamara R ^a   Locke, Kenneth W ^a  

^a Interneuron Pharmaceuticals Inc   (United States)

Author keywords

Acetylcholine; Cognition; D1 receptors; Dihydrexidine

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; QUINPIROLE; SCOPOLAMINE; ACETYLCHOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PHENANTHRIDINE DERIVATIVE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN REGION; COGNITION; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; PASSIVE AVOIDANCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; AVOIDANCE BEHAVIOR; DOSE RESPONSE; DRUG EFFECT; METABOLISM; SPRAGUE DAWLEY RAT;

ACETYLCHOLINE; ANIMALS; AVOIDANCE LEARNING; COGNITION; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICRODIALYSIS; PHENANTHRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030609832     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00290-6     Document Type: Article

References (50)

1. 1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology. 116:1994;143-151.
2. Bartus R. T., Dean R. L., Beer B., Lippa A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-414.
3. 2 dopaminergic regulation of acetylcholine release from striata of freely moving rats. J. Neurochem. 54:1990;2145-2148.
4. Braun A., Fabbrini G., Mouradian M. M., Serrati C., Barone P., Chase T. N. Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J. Neural. Transm. 68:1987;41-50.
5. 1 full agonist J. Med. Chem. 33:1990;1756-1764.
6. Broersen L. M., Heinsbroek R. P. W., de Bruin J. P. C., Joosten R. N. J. M. A., van Hest A., Olivier B. Effects of local application of dopaminergic drugs into the dorsal part of the medial prefrontal cortex of rats in a delayed matching to position task. comparison with local cholinergic blockade Brain Res. 645:1994;113-122.
7. Brozoski T. J., Brown R. M., Rosvold H. E., Goldman P. S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkeys. Science. 205:1979;929-932.
8. Castellano C., Cestari V., Cabib S., Puglisi-Allegra S. Post-training dopamine receptor agonists and antagonists affect memory storage in mice irrespective of their selectivity for D1 or D2 receptors. Behav. Neural Biol. 56:1991;283-291.
9. Consolo S., Girotti P., Russi G., Di Chiara G. Endogenous dopamine facilitates striatal in vivo acetylcholine release by acting on D1 receptors localized in the striatum. J. Neurochem. 59:1992;1555-1557.
10. Damsma G., DeBoer P., Westerink B. H., Fibiger H. C. Dopaminergic regulation of striatal acetylcholine release. an in vivo microdialysis study Naunyn-Schmiedeberg Arch. Pharmacol. 342:1990;523-527.
11. 1 receptor stimulation increases striatal acetylcholine release in the rat. Eur. J. Pharmacol. 186:1990;335-338.
12. Damsma G., Robertson G. S., Tham C.-S., Fibiger H. C. Dopaminergic regulation of striatal acetylcholine release. importance of D1 and N-methyl-D-aspartate receptors J. Pharmacol. Exp. Ther. 259:1991;1064-1072.
13. 1 dopamine receptor agonist. Neuropsychopharmacology. 5:1991;187-195.
14. DeBoer P., Damsma G., Schram Q., Stoof J. C., Zaagsma J., Westerink B. H. C. The effect of intrastriatal application of directly and indirectly acting dopamine agonists and antagonists on the in vivo release of acetylcholine measured by brain microdialysis. the importance of post-surgery interval Naunyn-Schmiedeberg Arch. Pharmacol. 345:1992;144-152.
15. 2 receptors in MPTP-induced hemiparkinsonian monkeys. J. Pharmacol. Exp. Ther. 265:1993;1387-1391.
16. Fibiger H. C., Damsma G., Day J. C. Behavioral pharmacology and biochemistry of central cholinergic neurotransmission. Adv. Exp. Biol. Med. 295:1991;399-414.
17. Imperato A., Obinu M. C., Dazzi L., Gessa G. L. Does dopamine exert a tonic inhibitory control on the release of striatal acetylcholine in vivo? Eur. J. Pharmacol. 251:1994;271-279.
18. Imperato A., Obinu M. C., Demontis M. V., Gessa G. L. Cocaine releases limbic acetylcholine through endogenous dopamine action on D1 receptors. Eur. J. Pharmacol. 229:1992;265-267.
19. 2 receptors facilitates in vivo acetylcholine release in the hippocampus. Brain Res. 618:1993;341-345.
20. Kebabian J. W., Britton D. R., DeNinno M. P., Perner R., Smith L., Jenner P., Schoenleber R., Williams M. A-77636. a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets Eur. J. Pharmacol. 229:1992;203-209.
21. Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
22. 2 agonists with scopolamine on radial-arm maze performance. Pharmacol. Biochem. Behav. 38:1991;243-246.
23. Lovenberg T. W., Brewster W. K., Mottola D. M., Lee R. C., Riggs R. M., Nichols D. E., Lewis M. H., Mailman R. B. Dihydrexidine, a novel selective, high potency full dopamine D-1 agonist. Eur. J. Pharmacol. 166:1989;111-113.
24. McGurk S. R., Levin E. D., Butcher L. L. Dopaminergic drugs reverse the impairment of radial-arm maze performance caused by lesions involving the cholinergic medial pathway. Neuroscience. 50:1992;129-135.
25. 1 dopamine receptor agonist. J. Pharmacol. Exp. Ther. 262:1992;383-393.
26. Olton D. S., Wenk G. L. Dementia. animal models of the cognitive impairments produced by degeneration of the basal forebrain cholinergic system Meltzer H. Y. Psychopharmacology. the third generation of progress:1987;941-953 Raven Press, New York.
27. Packard M. G., White N. M. Dissociation of hippocampus and caudate nucleus memory systems by posttraining intracerebral injection of dopamine agonists. Behav. Neurosci. 105:1991;295-306.
28. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 1982;Academic Press, Sydney.
29. Perry E. K., Perry R. H., Blessed G., Tomlinson B. E. Necropsy evidence of central cholinergic deficits in senile dementia. 1977;189, Lancet i.
30. Perry R. H., Tomlinson B. E., Candy J. M., Blessed G., Foster J. F., Bloxham C. A., Perry E. R. Cortical cholinergic deficit in mentally impaired parkinsonian patients. 1983;789-790, Lancet ii.
31. Robertson G. S., Hubert G. W., Tham C. S., Fibiger H. C. Lesions of the mesotelencephalic dopamine system enhance the effects of selective dopamine D1 and D2 receptor agonists on striatal acetylcholine release. Eur. J. Pharmacol. 219:1992;323-325.
32. Ruberg M., Ploska A., Javoy-Agid F., Agid Y. Muscarinic binding and choline acetyltransferase activity in parkinsonian subjects with reference to dementia. Brain Res. 232:1982;129-139.
33. Sawaguchi T., Goldman-Rakic P. S. The role of D1-dopamine receptor in working memory. local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task J. Neurophysiol. 71:1994;515-528.
34. Sawaguchi T., Goldman-Rakic P. S. D1 dopamine receptors in prefrontal cortex. involvement in working memory Science. 251:1991;947-950.
35. 1 dopamine receptors in dopaminergic control of striatal cholinergic neurotransmission. Life Sci. 31:1982;2883-2890.
36. Schneider J. S., Sun Z.-Q., Roeltgen D. P. Effects of dihydrexidine, a full dopamine D-1 agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res. 663:1994;140-144.
37. Sibley D. R., Monsma F. J. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13:1992;61-69.
38. Simon H., Scatton B., Le Moal M. Dopaminergic A10 neurones are involved in cognitive functions. Nature. 286:1980;150-151.
39. Simon H., Taghzouti K., LeMoal M. Deficits in spatial memory tasks following lesions of the septal dopaminergic terminals in the rat. Behav. Brain Res. 19:1986;7-16.
40. Spicer, M. A.; Elsworth, J. D.; Lawrence, M. S.; Roth, R. H.; Taylor, J. R.; Mailman, R. B.; Nichols, D. E.; Redmond, D. E., Jr.: Dihydrexidine in MPTP monkeys. Paper presented at the 1st International Meeting on Dopamine Agonists in Parkinson's Disease; 1993.
41. +-stimulated release of acetylcholine from rat neostriatum. Brain Res. 250:1982;263-270.
42. 1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur. J. Pharmacol. 199:1991;389-391.
43. Vermersch P., Delacourte A., Javoy-Agid F., Hauw J.-J., Agid Y. Dementia in Parkinson's disease. biochemical evidence for cortical involvement using the immunodetection of abnormal tau proteins Ann. Neurol. 33:1993;445-450.
44. Watkins P. B., Zimmerman H. J., Knapp M. J., Gracon S. I., Lewis K. W. Hepatotoxic effects of tacrine in patients with Alzheimer's disease. JAMA. 271:1994;992-998.
45. 1 receptors. efficacy of full (dihydrexidine) vs partial (SKF. 38393) agonists in primates vs. rodents. Eur. J. Pharmacol. 242:1993;165-172.
46. Whitehouse P. J. Pathology in the cholinergic basal forebrain. implications for treatment Adv. Exp. Biol. Med. 295:1991;447-452.
47. Whitehouse P. J., Price D. L., Clark A. W., Coyle J. T., DeLong M. R. Alzheimer's disease. evidence for selective loss of cholinergic neurons in the nucleus basalis Ann. Neurol. 10:1981;122-126.
48. Whitehouse P. J., Price D. L., Struble R. G., Clark A. W., Coyle J. T., DeLong M. R. Alzheimer's disease and senile dementia. loss of neurons in the basal forebrain Science. 215:1982;1237-1239.
49. Whitehouse P. J., Hedreen J. C., White C. L. I., Price D. L. Basal forebrain neurons in the dementia of Parkinson's disease. Ann. Neurol. 13:1983;243-248.
50. Winkler M. A. Tacrine for Alzheimer's disease. Which patient, what dose? JAMA. 271:1994;1023-1024.